Jeffrey W. Dunn Sells 7,965 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 7,965 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $17.69, for a total transaction of $140,900.85. Following the completion of the transaction, the director now owns 44,718 shares in the company, valued at $791,061.42. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

SI-BONE Stock Up 2.9 %

SI-BONE stock traded up $0.50 during mid-day trading on Monday, reaching $18.04. 230,933 shares of the company’s stock were exchanged, compared to its average volume of 355,422. The company has a market cap of $730.64 million, a P/E ratio of -15.16 and a beta of 0.99. SI-BONE, Inc. has a twelve month low of $11.14 and a twelve month high of $29.51. The company has a quick ratio of 9.74, a current ratio of 10.89 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average of $18.93 and a 200-day moving average of $22.72.

Analysts Set New Price Targets

SIBN has been the topic of several recent analyst reports. Cantor Fitzgerald decreased their target price on shares of SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Needham & Company LLC decreased their target price on shares of SI-BONE from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Morgan Stanley decreased their target price on shares of SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Finally, Truist Financial decreased their target price on shares of SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE presently has an average rating of “Buy” and an average price target of $27.17.

Institutional Investors Weigh In On SI-BONE

Large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its position in shares of SI-BONE by 1,018.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 214,990 shares of the company’s stock valued at $5,800,000 after purchasing an additional 195,769 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of SI-BONE by 8.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 660,911 shares of the company’s stock valued at $17,831,000 after purchasing an additional 50,482 shares during the last quarter. Mach 1 Financial Group LLC purchased a new position in shares of SI-BONE in the 2nd quarter valued at $552,000. Alpha DNA Investment Management LLC purchased a new position in shares of SI-BONE in the 2nd quarter valued at $780,000. Finally, Brown Advisory Inc. grew its position in shares of SI-BONE by 1.6% in the 1st quarter. Brown Advisory Inc. now owns 3,954,201 shares of the company’s stock valued at $77,779,000 after buying an additional 62,566 shares during the last quarter.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.